Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Exemption to Pharma Companies for R&D (India)

This article was originally published in PharmAsia News

Executive Summary

Ram Vilas Paswan, India's Union Chemicals and Fertilizer Minister, announced that the government is committed to giving the country's pharmaceutical companies up to a 150 percent margin for research and development. Paswan hopes doing so will encourage drug-makers to further lower the prices on essential medications. At the same time, Paswan said the current price controls instituted by the country are not enough. He turned a deaf ear to the industry's argument that the prices for many drugs in India are much lower than most countries. According to Paswan, drugs must be less expensive in India because 80 percent of the country's population must pay for medications themselves. To further help the situation, the government is also planning to introduce health insurance for many of India's poorest citizens. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel